who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

INCY · Q2 2026

Archived report (Q2 2026). Latest deep dive →

US GAAP, Q2 2026 · quarter ended 06/30/2026 · released Jul 28

Net income

$586M

up 44.6% y/y

Total revenues

$1,674M

up 37.7% y/y

Income from operations

$698M

up 31.6% y/y

The quarter in brief

Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M; diluted EPS was $2.81 versus $2.04.

All figures in $M.

Sankey diagram of INCY earnings report for Q2 2026: revenue, costs and profitNet sales$1,488 · +40.5%Product royalty revenues$175 · +15.6%Milestone and contractrevenues$11.2 · +124%Total revenues$1,674 · +37.7%Cost of sales(includingdefinite-livedintangibleamortization)$105 · +33.3%Research anddevelopment$517 · +4.5%Selling, generalandadministrative$352 · +6.3%Loss on change infair value ofacquisition-relatedcontingentconsideration$2.5 · −89.0%Income fromoperations$698 · +31.6%41.7% marginInterest income$38.1 · +51.6%Interest expense$0.6 · −2.0%Gain (loss) onequityinvestments$9.8 · vs −$4.2Other, net$6.3 · −14.1%Income beforeprovision forincome taxes$752 · +34.7%Provision for income taxes$166 · +8.4%22.1% effective rateNet income$586 · +44.6%$2.81/sh · 35.0% margin
Sankey diagram of INCY earnings report for Q2 2026: revenue, costs and profit
Line itemAmount and change
Net sales$1,488 · +40.5%
Product royalty revenues$175 · +15.6%
Milestone and contract revenues$11.2 · +124%
Total revenues$1,674 · +37.7%
Cost of sales (including definite-lived intangible amortization)$105 · +33.3%
Research and development$517 · +4.5%
Selling, general and administrative$352 · +6.3%
Loss on change in fair value of acquisition-related contingent consideration$2.5 · −89.0%
Income from operations$698 · +31.6% · 41.7% margin
Interest income$38.1 · +51.6%
Interest expense$0.6 · −2.0%
Gain (loss) on equity investments$9.8 · vs −$4.2
Other, net$6.3 · −14.1%
Income before provision for income taxes$752 · +34.7%
Provision for income taxes$166 · +8.4% · 22.1% effective rate
Net income$586 · +44.6% · $2.81/sh · 35.0% margin

Verdict: Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M; diluted EPS was $2.81 versus $2.04.

Source and notation

Source: INCY press release, 8-K EX-99.1 of 07/28/2026 (SEC EDGAR).

Open as an image: INCY, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “INCY Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/incy/q2-2026. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/incy/q2-2026"><img src="https://whoreportstoday.com/t/incy/q2-2026/sankey.png" alt="INCY Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/incy/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/incy/q2-2026/sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/incy/q2-2026">INCY Q2 2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

INCY — a biopharmaceutical company that discovers, develops and sells its own medicines in hematology, oncology, and inflammation and autoimmunity, including JAKAFI, OPZELURA cream and MONJUVI.

It earns money from product sales and from royalties and milestones paid by partners, such as on sales of JAKAVI outside the U.S.; the company reports a single segment. · Source: annual report (Form 10-K, SEC)

More reports: IQV · Q3 2026 · ISRG · Q3 2026 · JNJ · Q3 2026 · LH · Q3 2026 · LLY · Q3 2026 · MCK · Q2 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · all reports

Company reports

Q3 2026latest breakdownRevenue $1.56B (+14.0% y/y), operating loss $708M, net loss $785M.
Q2 2026Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M

Cookies the site needs and, with your consent, Google Analytics — privacy policy